Absci (Nasdaq: ABSI), a generative AI drug creation company, and PrecisionLife, a leader in computational biology, today announced a significant collaboration. This partnership is set to develop a portfolio of potential therapeutics, targeting unmet medical needs in chronic diseases. The collaboration leverages Absci’s prowess in antibody design and PrecisionLife’s expertise in complex disease biology, aiming to create a pipeline of novel biotherapeutics.

Joint Development of a Biotherapeutic Pipeline

Under the partnership, Absci and PrecisionLife will collaborate to discover and develop a shared pipeline of biotherapeutics for up to five mutually agreed-upon targets and indications. This cooperative effort will involve evaluating effective advancement strategies for programs targeting specific chronic disease drug targets, especially those linked to patients with unmet clinical needs.

Maximizing Innovation Potential

The partnership intends to harness the innovation potential of Absci’s AI-driven approach and PrecisionLife’s deep understanding of complex disease biology. Both companies will share in the potential value of programs developed against specific targets, merging their strengths to create impactful therapeutic solutions.

Leadership Comments on the Collaboration

Sean McClain, Founder & CEO of Absci, expressed enthusiasm for the partnership, noting the synergy of Absci’s AI capabilities with PrecisionLife’s disease biology insights. Steve Gardner, CEO & Co-founder of PrecisionLife, also shared his excitement, highlighting the transformative potential of their combined approaches to accelerate the development of new precision medicines for patients with unmet medical needs.

Expanding Absci’s Active Programs and Outlook for 2023

This partnership marks Absci’s tenth new Active Program signed this year, successfully achieving the company’s outlook for 2023. It signifies a milestone in the company’s journey towards leveraging AI in drug development, especially in the challenging area of chronic diseases.

Conclusion:

The collaboration between Absci and PrecisionLife represents a significant step forward in the quest to address chronic diseases through innovative therapeutic solutions. Combining generative AI with computational biology, this partnership aims to revolutionize the development of precision medicines and meet the pressing needs of patients worldwide.

  Absci, Drug discovery, PrecisionLife, Sean McClain, Steve Gardner